571 related articles for article (PubMed ID: 28558833)
1. Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol.
Singh D; D'Urzo AD; Chuecos F; Muñoz A; Garcia Gil E
Respir Res; 2017 May; 18(1):106. PubMed ID: 28558833
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study.
D'Urzo AD; Rennard SI; Kerwin EM; Mergel V; Leselbaum AR; Caracta CF;
Respir Res; 2014 Oct; 15(1):123. PubMed ID: 25756831
[TBL] [Abstract][Full Text] [Related]
3. The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorized by symptom status: a pooled analysis.
Miravitlles M; Chapman KR; Chuecos F; Ribera A; Gil EG
Int J Chron Obstruct Pulmon Dis; 2016; 11():2041-53. PubMed ID: 27621610
[TBL] [Abstract][Full Text] [Related]
4. ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD.
Watz H; Troosters T; Beeh KM; Garcia-Aymerich J; Paggiaro P; Molins E; Notari M; Zapata A; Jarreta D; Garcia Gil E
Int J Chron Obstruct Pulmon Dis; 2017; 12():2545-2558. PubMed ID: 28883722
[TBL] [Abstract][Full Text] [Related]
5. Combined aclidinium bromide and long-acting beta2-agonist for chronic obstructive pulmonary disease (COPD).
Ni H; Moe S; Soe Z; Myint KT; Viswanathan KN
Cochrane Database Syst Rev; 2018 Dec; 12(12):CD011594. PubMed ID: 30536566
[TBL] [Abstract][Full Text] [Related]
6. Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT).
Bateman ED; Chapman KR; Singh D; D'Urzo AD; Molins E; Leselbaum A; Gil EG
Respir Res; 2015 Aug; 16(1):92. PubMed ID: 26233481
[TBL] [Abstract][Full Text] [Related]
7. Extrafine triple therapy delays COPD clinically important deterioration vs ICS/LABA, LAMA, or LABA/LAMA.
Singh D; Fabbri LM; Vezzoli S; Petruzzelli S; Papi A
Int J Chron Obstruct Pulmon Dis; 2019; 14():531-546. PubMed ID: 30880943
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of aclidinium/formoterol 400/12 µg, analyzed by airflow obstruction severity, age, sex, and exacerbation history: pooled analysis of ACLIFORM and AUGMENT.
D'Urzo AD; Singh D; Donohue JF; Kerwin EM; Ribera A; Molins E; Chuecos F; Jarreta D; Gil EG
Int J Chron Obstruct Pulmon Dis; 2019; 14():479-491. PubMed ID: 30880938
[TBL] [Abstract][Full Text] [Related]
9. A randomised double-blind, placebo-controlled, long-term extension study of the efficacy, safety and tolerability of fixed-dose combinations of aclidinium/formoterol or monotherapy in the treatment of chronic obstructive pulmonary disease.
D'Urzo A; Rennard S; Kerwin E; Donohue JF; Lei A; Molins E; Leselbaum A
Respir Med; 2017 Apr; 125():39-48. PubMed ID: 28340861
[TBL] [Abstract][Full Text] [Related]
10. AMPLIFY: a randomized, Phase III study evaluating the efficacy and safety of aclidinium/formoterol vs monocomponents and tiotropium in patients with moderate-to-very severe symptomatic COPD.
Sethi S; Kerwin E; Watz H; Ferguson GT; Mroz RM; Segarra R; Molins E; Jarreta D; Garcia Gil E
Int J Chron Obstruct Pulmon Dis; 2019; 14():667-682. PubMed ID: 30962681
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Aclidinium/Formoterol versus Tiotropium in COPD: Results of an Indirect Treatment Comparison.
Medic G; Lindner L; van der Weijden M; Karabis A
Adv Ther; 2016 Mar; 33(3):379-99. PubMed ID: 26883661
[TBL] [Abstract][Full Text] [Related]
12. Efficacy And Safety Of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (GFF MDI) Formulated Using Co-Suspension Delivery Technology In Chinese Patients With COPD.
Chen R; Zhong N; Wang HY; Zhao L; Mei X; Qin Z; Huang J; Assam PN; Maes A; Siddiqui S; Martin UJ; Reisner C
Int J Chron Obstruct Pulmon Dis; 2020; 15():43-56. PubMed ID: 32021143
[TBL] [Abstract][Full Text] [Related]
13. Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Lung Function versus Monotherapies in GOLD Category A Patients with COPD: Pooled Data from the Phase III PINNACLE Studies.
Martinez FJ; Rabe KF; Lipworth BJ; Arora S; Jenkins M; Martin UJ; Reisner C
Int J Chron Obstruct Pulmon Dis; 2020; 15():99-106. PubMed ID: 32021148
[TBL] [Abstract][Full Text] [Related]
14. An Evaluation Of Single And Dual Long-Acting Bronchodilator Therapy As Effective Interventions In Maintenance Therapy-Naïve Patients With COPD.
Singh D; D'Urzo AD; Donohue JF; Kerwin EM; Molins E; Chuecos F; Ribera A; Jarreta D
Int J Chron Obstruct Pulmon Dis; 2019; 14():2835-2848. PubMed ID: 31827323
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of aclidinium/formoterol versus monotherapies and aclidinium versus placebo in Chinese and other Asian patients with moderate-to-severe COPD: The AVANT Phase 3 study.
Sun Y; Molins E; Daoud SZ; Trivedi R; Stewart C; Lamarca R; Bharali P; Garcia-Gil E
Respir Med; 2023 Nov; 218():107393. PubMed ID: 37640273
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of aclidinium bromide in patients with COPD: A phase 3 randomized clinical trial in a Korean population.
Lee SH; Lee J; Yoo KH; Uh ST; Park MJ; Lee SY; Kim JY; Kim DK; Kim SJ; Lee KH; Yoo CG
Respirology; 2015 Nov; 20(8):1222-8. PubMed ID: 26370136
[TBL] [Abstract][Full Text] [Related]
17. Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol.
Singh D; Maleki-Yazdi MR; Tombs L; Iqbal A; Fahy WA; Naya I
Int J Chron Obstruct Pulmon Dis; 2016; 11():1413-24. PubMed ID: 27445468
[TBL] [Abstract][Full Text] [Related]
18. Long-term safety of aclidinium bromide/formoterol fumarate fixed-dose combination: Results of a randomized 1-year trial in patients with COPD.
Donohue JF; Soong W; Wu X; Shrestha P; Lei A
Respir Med; 2016 Jul; 116():41-8. PubMed ID: 27296819
[TBL] [Abstract][Full Text] [Related]
19. Benefits of glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) in improving lung function and reducing exacerbations in patients with moderate-to-very severe COPD: a pooled analysis of the PINNACLE studies.
Martinez FJ; Lipworth BJ; Rabe KF; Collier DJ; Ferguson GT; Sethi S; Feldman GJ; O'Brien G; Jenkins M; Reisner C
Respir Res; 2020 May; 21(1):128. PubMed ID: 32450869
[TBL] [Abstract][Full Text] [Related]
20. Comparative efficacy of aclidinium versus glycopyrronium and tiotropium, as maintenance treatment of moderate to severe COPD patients: a systematic review and network meta-analysis.
Karabis A; Lindner L; Mocarski M; Huisman E; Greening A
Int J Chron Obstruct Pulmon Dis; 2013; 8():405-23. PubMed ID: 24043936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]